

Animal health drives sales as poultry decline continues; margins decline...

About the stock: Hester is one of India's leading animal healthcare companies & the second largest poultry vaccine manufacturer in the country. It has a strategic presence in 30+ countries with key markets being India, Nepal and Tanzania.

- It operates through four broad verticals: poultry vaccines, poultry health products, animal vaccines and animal health products
- Revenue segment wise: poultry healthcare: 49%, animal healthcare: 51%

Q2FY23 Results: Numbers were weak on the margin front as sales mix changed.

- Sales were up 15% YoY to ₹ 72 crore
- EBITDA was at ₹ 15.8 crore, down 10% YoY with margins at 21.9%. Margins declined amid a change in the sales mix
- Adjusted PAT was at ₹ 10.4 crore (down 2.5% YoY)

What should investors do? Hester's share price has grown by ~1.2x over the past three years (from ~₹ 1631 in November 2019 to ~₹ 2000 levels in November 2022).

- Upgraded from REDUCE to **HOLD** but maintain neutral stance as we monitor ramp-up in Animal Healthcare, Africa business, opportunities in pet-care to mitigate slump in legacy poultry vaccines segment

Target Price and Valuation: We value Hester at ₹ 2070 (base business at ₹ 2051 i.e. 35x FY24E EPS of ₹ 58.6 + NPV of ₹ 16 for Covaxin DS opportunity).

Key triggers for future price performance:

- Opportunities in animal vaccines such as classical swine fever, lumpy skin disease (only player), sheep pox (only player) in the domestic space and expected launch of the modified Inactivated Coryza Vaccine, along with additional revenue from PPR national tender
- Increased focus on health products & widening of portfolio with differentiated herbal line of products looks promising for growth prospects
- Traction from manufacturing from Tanzania facility, Hester Africa and strengthened distribution network in Africa, along with increase in bulk antigen capacity and fill finish line for animal vaccines
- Foray into pet care with 10 products and new marketing teams in four zones


Alternate Stock Idea: Apart from Hester, in our healthcare coverage we like Indoco.

- Indoco manufactures and markets branded formulations and APIs for the domestic and export markets
- BUY with target price of ₹ 525



Particulars	
Particular	Amount
Market Capitalisation	₹ 1701 crore
Debt (FY22)	₹ 223 crore
Cash (FY22)	₹ 25 crore
EV	₹ 1899 crore
52 week H/L (₹)	2852/1964
Equity capital	₹ 8.5 crore
Face value (₹)	₹ 10

Shareholding pattern				
(in %)	Dec-21	Mar-22	Jun-22	Sep-22
Promoter	53.7	53.7	53.7	53.7
Others	46.3	46.3	46.3	46.3



Recent Event & Key risks

- Acquired 50% stake in Thrishool Exim, Tanzania
- **Key Risk:** (i) Prolonged logistical challenges in exports (ii) Faster ramp up of new launches

Research Analyst

Siddhant Khandekar
siddhant.khandekar@icicisecurities.com

Utkarsh Jain
utkarsh.jain@icicisecurities.com

Key Financial Summary

Key Financials (₹ Crore)	FY20	FY21	FY22	5 year CAGR (FY17-22)	FY23E	FY24E	2 year CAGR (FY22-24E)
Revenues	183.3	214.3	235.0	13.8	261.7	292.8	11.6
EBITDA	55.4	68.7	60.0	8.0	54.9	70.0	8.0
EBITDA margins(%)	30.2	32.0	25.5		21.0	23.9	
Adjusted Net Profit	29.2	37.8	38.9	10.7	32.1	49.8	13.2
EPS (₹)	34.3	44.4	45.7		37.8	58.6	
PE (x)	58.3	49.4	43.7		52.9	34.1	
EV to EBITDA (x)	32.6	26.0	31.7		34.5	26.8	
RoNW (%)	14.5	16.5	15.0		11.3	15.4	
RoCE (%)	14.0	16.2	10.9		9.5	12.7	

Source: Company, ICICI Direct Research

Key takeaways of recent quarter & conference call highlights

Q2FY23 Results: Animal healthcare boosts revenue, margins impacted

- Hester reported 27% YoY growth to ₹ 72 crore, driven by 24% growth in vaccines and 36% growth in animal healthcare. However, EBITDA margins shrank from 30% to 22% as significant sales came from low margins large animal vaccine sales, which are mainly tender driven. Adjusted net profit came at ₹ 10.4 crore, down 2.5% YoY
- The company is in a phase to transform itself from a veterinary vaccine player to animal health provider. This long drawn journey is likely to have impact on EBITDA margins for some time. Going ahead, Hester is expected to focus on vaccine tailwinds on the back of LSD outbreak and PPR tender while improving sales productivity and scaling-up health products remain key for better operating leverage. As Hester strengthens its hold in the animal healthcare space, order flow and pricing power is likely to improve

Q2FY23 Earnings Conference Call highlights

- Vaccine sales declined 30% YoY in Q1FY23 due to high base as Q1FY22 hugely benefited from one-off sales on account of the then prevailing poultry disease outbreak while in this quarter poultry industry continued to face strong headwinds on account of increased cost of inputs (mainly feed) and pricing pressure on eggs and broiler birds. Consequent to severe margin pressure, the poultry industry sharply reduced new bird placements along-with initiatives towards input cost optimisation
- Sales of health products grew 42% on the back of strong momentum gained from new product and territorial expansion. Overall margins have reduced due to the increase in the proportion of health products sales which have lower gross margins compared to vaccines. Health products sales constituted 34% of the total sales in Q1FY23, vs. 20% in Q1FY22
- EBITDA and PAT margin declined in Q1FY23 due to reduction in vaccine sales, increase in marketing expenses on a low base, increased market development cost in animal health and petcare divisions on account of company's continuous efforts in expansion activities
- Going forward, the management expects the recent outbreak of lumpy skin disease (LSD) to result in additional sales in Q2FY23 while supplies for government tender for PPR vaccine for sheep & goat to start from September 2022
- Over the next couple of quarters, Hester will focus on growing sales of health products on the back of improving sales productivity of the marketing team as well as launching new products and entering new territories
- In pet care division, in Q1 10 products were launched in the market and sales force has been employed. The company is implementing distributorship model for supply chain on similar lines to poultry and health products.
- Hester Nepal has registered 16% growth in domestic revenues but there were no tender sales due to delay in tendering by FAO and other multilateral institutions. Hester Tanzania started commercial operations and received regulatory approval for four products with two additional products under approval process. Revenues are expected to start in Q2FY23
- Bulk antigen production capacity expansion project is completed and trial runs are ongoing with commercialisation expected from Q4FY23. Expansion of Fill-Finish line capacity is expected to be completed by Q4
- Government of India has allowed the manufacture and sale of Avian Influenza Inactivated vaccine, H9N2 strain, to contribute from Q3

Exhibit 1: Variance Analysis

	Q2FY23	Q2FY23E	Q2FY22	Q1FY23	YoY (%)	QoQ (%)	Comments
Revenue	72.0	61.3	62.7	50.7	15.0	42.1	YoY improvement driven by 24% growth in vaccines, 36% growth in animal healthcare
Raw Material Expenses	21.6	17.2	16.2	14.4	33.9	50.6	
Gross Margin (%)	70.0	72.0	74.2	71.7	-423.9	-169.7	Sequential decline impacted due to increase in proportion of sales of health products coupled with an increase in input prices for poultry
Employee Expenses	13.0	12.3	11.1	11.8	17.3	10.1	
Other Expenditure	21.6	17.2	17.8	17.1	20.9	26.4	
EBITDA	15.8	14.7	17.6	7.4	-10.0	112.8	
EBITDA (%)	21.9	24.0	28.0	14.7	-607.2	729.2	EBITDA margins shrank from 30% to 22% as significant sales came from low margins large animal vaccine sales, which are mainly tender driven
Interest	1.7	1.7	0.7	1.6	134.9	8.9	
Depreciation	2.3	5.5	3.1	5.1	-23.4	-53.8	
Other Income	2.2	3.1	1.4	3.1	52.9	-30.3	
PBT before EO & Forex	13.9	10.6	15.2	5.5	-8.4	154.5	
Forex & EO	0.0	0.0	0.0	0.0			
PBT	13.9	10.6	15.2	5.5	-8.4	154.5	
Tax	3.5	2.8	4.1	1.9	-13.0	85.7	
PAT before MI	10.4	7.8	11.1	3.6	-6.8	191.3	
MI	0.0	0.6	0.5	-0.4	-96.4	-104.4	
Adjusted Net Profit	10.4	7.2	10.6	4.0	-2.5	160.9	Delta vis-à-vis EBITDA
Key Metrics							
Poultry Healthcare	35.5	43.2	45.5	38.4	-22.0	-7.7	The poultry industry continues to be under pressure to high feed costs and low product realisations
Animal Healthcare	36.6	18.1	17.2	12.3	112.4	197.1	Growth driven by the spurt in the demand for the goat pox vaccine to control the outbreak of lumpy skin disease (LSD) in cattle in the country

Source: Company, ICICI Direct Research

Exhibit 2: Change in estimates

(₹ Crore)	FY23E			FY24E			Comments
	Old	New	Change	Old	New	Change	
Revenue	268.2	261.7	-2.4	302.6	292.8	-3.2	Changed on the back of poor offtake in Africa and lower than expected sales in poultry business
EBITDA	63.4	54.9	-13.5	88.2	70.0	-20.7	
EBITDA Margin (%)	23.6	21.0	-268 bps	29.2	23.9	-525 bps	Changed mainly because of increasing operational expenses and lower margin profile for animal health
PAT	35.1	32.1	-8.5	53.8	49.8	-7.3	
EPS (₹)	41.3	37.8	-8.5	63.2	58.6	-7.3	

Source: ICICI Direct Research

Exhibit 3: Assumptions

(₹ crore)	Current				Earlier				Comments
	FY20	FY21	FY22	FY23E	FY24E	FY23E	FY24E		
Poultry Healthcare	120.3	156.5	171.8	181.4	199.5	192.0	215.1	Changed due to adverse demand environment	
Animal Healthcare	47.3	50.5	63.2	71.5	82.2	76.1	87.5	Changed as the offtake is slower than anticipated	

Source: ICICI Direct Research

Exhibit 4: Trends in Quarterly Performance

(₹ crore)	Q1FY20	Q2FY20	Q3FY20	Q4FY20	Q1FY21	Q2FY21	Q3FY21	Q4FY21	Q1FY22	Q2FY22	Q3FY22	Q4FY22	Q1FY23	YoY (%)	QoQ (%)
Total Operating Income	44.8	44.2	50.7	43.6	39.9	53.4	56.9	64.2	60.2	62.7	55.7	56.5	50.7	-15.8	-10.2
Raw Material Expenses	5.6	5.6	5.7	2.9	5.0	15.2	13.7	17.7	17.9	16.2	13.3	15.4	14.4	-19.6	-6.8
% of Revenue	12.5	12.6	11.2	6.5	12.4	28.5	24.0	27.5	29.7	25.8	23.9	27.3	28.3	-135 bps	105 bps
Gross Profit	39.2	38.6	45.0	40.8	34.9	38.2	43.2	46.5	42.3	46.5	42.4	41.1	36.3	-14.1	-11.5
Gross Profit Margin (%)	87.5	87.4	88.8	93.5	87.6	71.5	76.0	72.5	70.3	74.2	76.1	72.7	71.7	135 bps	-105 bps
Employee Expenses	8.6	9.4	10.3	12.4	8.6	8.4	10.8	11.1	11.3	11.1	10.7	12.3	11.8	5.0	-3.4
% of Revenue	19.3	21.2	20.3	28.5	21.5	15.8	19.0	17.4	18.8	17.7	19.1	21.7	23.4	461 bps	165 bps
Other Expenditure	13.0	18.2	14.0	21.2	14.4	14.0	11.2	15.6	14.0	17.8	16.7	18.5	17.1	22.1	-7.7
% of Revenue	29.0	41.2	27.7	48.5	36.2	26.2	19.8	24.3	23.2	28.5	30.0	32.7	33.7	1044 bps	93 bps
Total Expenditure	27.2	33.1	30.0	36.4	28.0	37.6	35.7	44.4	43.1	45.1	40.7	46.1	43.3	0.3	-6.2
% of Revenue	60.7	75.0	59.2	83.5	70.1	70.4	62.8	69.2	71.6	72.0	73.0	81.7	85.3	1370 bps	363 bps
EBITDA	17.6	11.1	20.7	7.2	11.9	15.8	21.2	19.8	17.1	17.6	15.0	10.3	7.4	-56.5	-28.0
EBITDA Margin (%)	39.3	25.0	40.8	16.5	29.9	29.6	37.2	30.8	28.4	28.0	27.0	18.3	14.7	-1370 bps	-363 bps
Other Income	0.6	0.7	0.3	4.8	0.7	0.2	1.3	2.5	2.3	1.4	2.8	7.2	3.1	33.0	-56.6
Interest	1.9	1.4	2.6	2.5	1.5	2.1	1.5	1.4	0.9	0.7	1.0	1.5	1.6	86.2	6.7
Depreciation	3.2	3.2	3.4	3.2	3.2	3.2	3.3	3.6	3.2	3.1	5.2	5.1	5.1	56.7	-1.4
PBT	13.0	7.1	15.0	6.2	7.9	10.7	17.7	17.2	15.3	15.2	11.7	10.9	3.9	-74.6	-64.2
Total Tax	4.9	0.9	3.0	1.5	2.8	4.0	4.8	3.8	4.3	4.1	3.3	2.3	1.9	-55.8	-17.3
Tax rate (%)	37.9	12.7	20.1	23.7	35.9	37.5	27.1	21.9	28.1	26.7	28.7	21.1	48.9	2078 bps	2775 bps
PAT	8.4	6.5	11.5	2.7	5.7	6.7	12.3	9.7	12.5	10.6	8.5	7.7	4.0	-68.2	-48.6
PAT Margin (%)	18.7	14.8	22.7	6.3	14.3	12.5	21.7	15.1	20.8	17.0	15.2	13.7	7.8		
EPS (₹)	9.9	7.7	13.5	3.2	6.7	7.9	14.5	11.4	14.7	12.5	10.0	9.1	4.7		

Source: ICICI Direct Research

Exhibit 5: ICICI Direct Coverage Universe (Healthcare)

Company	I-Direct Code	CMP (₹)	TP (₹)	Rating	M Cap (₹ cr)	EPS (₹)				PE(x)				RoCE (%)				RoE (%)			
						FY21	FY22	FY23E	FY24E	FY21	FY22	FY23E	FY24E	FY21	FY22	FY23E	FY24E	FY21	FY22	FY23E	FY24E
Hospitals																					
Apollo Hospitals	APOHOS	4352	5,080	Buy	62577	7.9	59.1	79.0	101.0	553.7	73.6	55.1	43.1	6.3	15.1	15.3	18.8	2.5	15.1	17.4	18.9
Narayana Hrudalaya	NARHRU	697	800	Buy	14240	-0.7	16.7	20.6	22.7	NA	41.6	33.9	30.7	1.2	20.5	19.6	19.7	-1.3	23.0	22.3	19.9
Shalby	SHALIM	120	150	Buy	1292	3.9	5.4	7.5	9.9	30.5	22.1	16.0	12.1	6.5	8.4	11.7	14.3	5.1	6.7	8.6	10.4
Aster DM	ASTDM	206	250	Buy	10300	3.0	10.5	10.8	16.7	69.7	19.6	19.1	12.4	5.4	9.0	9.4	12.5	4.4	13.3	12.0	15.6
Healthcare Global	HEAGLO	284	345	Buy	3947	-13.9	3.9	4.5	8.8	-13.9	73.5	62.4	32.1	-0.9	5.0	9.4	12.1	-0.9	5.0	6.8	11.6
MNC Pharma																					
Abbott India	ABBIND	19152	21,140	Hold	40696	325.0	375.9	427.7	528.6	58.9	51.0	44.8	36.2	33.8	36.6	37.1	37.3	26.5	28.3	28.9	28.8
P&G Health	MERLIM	4403	4,955	Hold	7309	106.5	121.5	130.5	141.6	41.3	36.2	33.7	31.1	32.2	37.3	34.7	32.8	25.1	29.3	27.0	25.4
Sanofi India	SANOFI	6355	6,885	Hold	14637	207.4	410.1	270.5	264.8	30.6	15.5	23.5	24.0	32.3	33.3	41.1	50.7	24.5	25.9	31.2	38.7
Pfizer	PFIZER	4257	4,480	Hold	19475	108.8	133.9	140.4	149.3	39.1	31.8	30.3	28.5	27.6	26.1	22.4	21.8	20.8	21.4	17.9	17.7
Pharma																					
Ajanta Pharma	AJAPHA	1272	1,495	Buy	16298	51.0	55.6	60.1	71.1	24.9	22.9	21.2	17.9	29.0	27.0	24.4	24.5	21.8	21.8	19.9	19.9
Alembic Pharma	ALEMPHA	663	590	Reduce	13030	62.8	27.8	15.3	26.9	10.6	23.9	43.4	24.6	25.1	10.6	6.5	10.5	24.1	10.4	5.6	9.1
Aurobindo Pharma	AURPHA	588	615	Hold	34430	55.0	47.4	41.1	51.3	10.7	12.4	14.3	11.5	16.9	12.9	11.5	13.3	14.7	11.3	9.0	10.1
Biocon	BIOCON	315	320	Hold	37819	6.3	5.7	5.5	11.3	50.3	55.3	57.8	27.8	7.7	7.5	4.1	6.5	9.9	8.1	2.8	5.5
Zydus Lifesciences	CADHEA	394	405	Hold	39891	23.3	21.0	21.0	23.8	16.9	18.8	18.8	16.6	13.8	12.0	11.8	11.7	18.4	12.6	11.4	11.6
Cipla	CIPLA	1030	1,135	Buy	83148	29.9	32.9	38.6	45.8	34.5	31.3	26.7	22.5	16.3	16.7	17.9	19.0	13.1	12.7	13.3	14.1
Dr Reddy's Labs	DRREDD	4306	4,750	Buy	71668	117.3	126.9	203.4	191.0	36.7	33.9	21.2	22.5	13.1	13.0	19.1	18.1	11.1	11.0	15.4	13.0
Glenmark Pharma	GLEPHA	387	460	Hold	10911	32.9	42.7	41.0	48.3	11.8	9.1	9.4	8.0	13.9	14.8	14.5	15.4	13.1	13.2	11.4	11.9
Ipca Laboratories	IPCLAB	929	985	Hold	23560	44.9	34.8	27.5	35.1	20.7	26.7	33.8	26.4	27.1	17.4	14.3	16.3	24.2	16.1	11.4	13.0
Jubilant Pharmova	JUBLIF	345	340	Reduce	5495	37.4	26.0	15.9	26.1	9.2	13.3	21.7	13.2	13.7	9.0	6.1	8.6	12.6	7.8	4.6	7.0
Lupin	LUPIN	681	610	Reduce	30980	26.9	11.9	11.8	27.7	25.4	57.4	57.9	24.6	9.6	3.4	5.8	10.9	8.8	4.4	4.2	9.2
Natco Pharma	NATPHA	656	735	Hold	11969	24.2	9.3	41.6	42.3	27.1	70.4	15.8	15.5	13.1	4.6	18.1	16.9	10.7	4.0	15.5	13.9
Sun Pharma	SUNPHA	918	1,125	Buy	220151	30.0	32.0	34.8	40.1	30.5	28.7	26.4	22.9	14.2	18.2	18.0	18.7	15.5	16.0	15.2	15.2
Torrent Pharma	TORPHA	1580	1,800	Buy	53459	37.0	32.0	43.7	54.6	42.7	49.3	36.2	29.0	17.6	19.7	24.7	29.4	21.4	18.2	20.9	21.8
Indoco Remedies	INDREM	372	525	Buy	3429	10.1	16.8	21.6	29.2	36.9	22.2	17.2	12.8	11.7	17.5	17.6	23.9	12.1	17.1	18.6	20.6
Caplin Point	CAPPOI	811	1,000	Buy	6146	81.7	85.3	70.4	73.0	9.9	9.5	11.5	11.1	25.3	23.7	22.6	0.0	20.4	20.2	18.7	17.5
Advanced Enzymes	ADVENZ	270	265	Reduce	3017	13.1	10.7	8.5	12.1	20.6	25.2	31.9	22.4	19.4	14.3	10.2	13.2	15.1	11.0	8.1	10.4
Hester Biosciences	HESPHA	2125	2,015	Reduce	1808	44.4	45.7	35.9	51.8	47.9	46.5	59.2	41.1	16.2	10.9	9.3	11.8	16.5	15.0	10.8	14.0
API/CRAMS																					
Divi's Lab	DIVLAB	3745	4,315	Buy	99406	74.7	111.5	93.0	113.5	50.1	33.6	40.3	33.0	27.6	30.2	22.8	24.4	21.3	25.2	18.4	19.2
Hikal	HIKCHE	293	290	Hold	3618	10.8	13.0	3.8	14.4	27.2	22.5	76.6	20.3	15.1	13.6	5.6	13.8	14.3	15.0	4.3	14.2
Syngene Int.	SYNINT	587	710	Buy	23568	10.1	9.9	11.5	14.6	58.0	59.5	50.9	40.3	11.5	11.7	12.8	15.2	13.5	12.9	12.4	13.7
Granules India	GRANUL	316	375	Buy	7837	22.2	16.6	21.9	26.8	14.3	19.0	14.4	11.8	24.0	15.6	18.6	20.5	25.3	16.0	17.6	17.9
Laurus Labs	LAULAB	572	675	Buy	30737	18.3	15.4	20.7	27.0	31.3	37.1	27.6	21.2	31.7	21.3	23.6	26.0	37.9	24.7	25.6	25.6
Suven Pharmaceuticals	SUVPH	449	530	Hold	11436	14.2	17.8	17.0	17.6	31.6	25.2	26.4	25.5	31.2	37.5	28.7	25.0	30.7	29.7	23.0	20.0

Source: ICICI Direct Research

Financial Summary

Exhibit 6: Profit and loss statement				
	₹ crore			
(Year-end March)	FY21	FY22	FY23E	FY24E
Revenues	214.3	235.0	261.7	292.8
Growth (%)	17.0	9.6	11.4	11.9
Raw Material Expenses	51.5	62.7	76.3	82.0
Employee Expenses	38.9	45.3	51.0	57.1
Other Expenditure	55.3	67.0	79.6	83.7
Total Operating Expenditure	145.7	175.0	206.9	222.8
EBITDA	68.7	60.0	54.9	70.0
Growth (%)	23.9	-12.6	-8.5	27.6
Interest	6.6	4.1	6.8	6.7
Depreciation	13.3	16.6	12.1	9.9
Other Income	4.7	13.7	9.5	14.6
PBT before Exceptional Items	53.4	53.1	45.5	68.1
Less: Forex & Exceptional Items	3.3	0.0	0.0	0.0
PBT	50.1	53.1	45.5	68.1
Total Tax	15.4	14.0	12.5	17.3
PAT	34.4	38.9	32.1	49.8
Adjusted PAT	37.8	38.9	32.1	49.8
Growth (%)	29.4	3.0	-17.4	55.1
EPS	40.5	45.7	37.8	58.6
EPS (Adjusted)	44.4	45.7	37.8	58.6

Source: Company, ICICI Direct Research

Exhibit 7: Cash flow statement				
	₹ crore			
(Year-end March)	FY21	FY22	FY23E	FY24E
Profit/(Loss) after taxation	36.2	36.4	32.1	49.8
Add: Depreciation & Amortization	13.3	16.6	12.1	9.9
Add: Interest	4.0	2.6	6.8	6.7
Net Increase in Current Assets	14.2	-29.1	-24.6	-16.1
Net Increase in Current Liabilities	-15.0	-9.5	4.7	2.7
CF from operating activities	52.7	16.9	31.1	52.9
(Inc)/dec in Fixed Assets	-40.7	-95.5	-30.0	-20.0
(Inc)/dec in Investments	0.0	-21.3	21.2	0.0
Other Investing Activities	-1.0	-0.1	0.7	0.7
CF from investing activities	-41.7	-116.9	-8.1	-19.3
Proceeds from issues of Equity Sh:	0.0	0.4	0.0	0.0
Proceeds/(Repayment) Loan	-22.9	116.9	0.0	0.0
(Payment) of Dividend and Dividend	-5.6	-8.5	-7.7	-11.5
Other Financing Activities	10.3	2.9	-6.8	-6.7
CF from financing activities	-18.2	111.6	-14.5	-18.2
Net Cash flow	-7.2	11.6	8.5	15.5
Opening Cash	23.5	21.7	25.2	33.7
Closing Cash	16.4	33.3	33.7	49.2
FCF	12.0	-78.7	1.1	32.9

Source: Company, ICICI Direct Research

Exhibit 8: Balance Sheet				
	₹ crore			
(Year-end March)	FY21	FY22	FY23E	FY24E
Equity Capital	8.5	8.5	8.5	8.5
Reserve and Surplus	219.8	251.5	276.0	314.3
Total Shareholders funds	228.3	260.0	284.5	322.8
Total Debt	104.5	222.6	222.6	222.6
Deferred Tax Liability	7.3	6.5	6.8	7.2
Minority Interest	7.7	7.4	7.8	8.2
Other Non Current Liabilities	23.6	26.8	28.2	29.6
Source of Funds	371.4	523.3	549.8	590.3
Gross Block - Fixed Assets	228.2	348.2	368.2	388.2
Accumulated Depreciation	95.4	111.0	123.1	132.9
Net Block	132.8	237.2	245.1	255.2
Capital WIP	109.0	81.9	91.9	91.9
Net Fixed Assets	241.8	319.1	337.0	347.2
Total Intangible Assets	0.0	0.0	0.0	0.0
Investments	0.0	21.2	0.0	0.0
Inventory	62.2	75.4	91.7	98.5
Cash	21.7	25.2	33.7	49.2
Debtors	49.2	55.3	61.6	68.9
Loans & Advances & Other CA	28.4	38.9	40.8	42.9
Total Current Assets	161.5	194.8	227.9	259.5
Creditors	28.1	18.0	21.9	23.6
Provisions & Other CL	11.6	20.9	21.6	22.7
Total Current Liabilities	39.7	38.9	43.5	46.2
Net Current Assets	121.8	155.9	184.4	213.3
LT L& A, Other Assets	7.8	27.1	28.4	29.9
Deferred Tax Assets	0.0	0.0	0.0	0.0
Application of Funds	371.4	523.3	549.8	590.3

Source: Company, ICICI Direct Research

Exhibit 9: Key ratios				
(Year-end March)	FY21	FY22	FY23E	FY24E
Per share data (₹)				
EPS	44.4	45.7	37.8	58.6
Cash EPS	34.4	35.7	28.8	45.1
BV	268.4	305.6	334.4	379.5
DPS	10.0	10.0	9.0	13.5
Cash Per Share	112.1	130.5	144.7	156.2
Operating Ratios (%)				
Gross Profit Margins	76.0	73.3	70.8	72.0
EBITDA margins	32.0	25.5	21.0	23.9
Net Profit margins	17.6	16.6	12.3	17.0
Inventory days	441.0	438.7	438.7	438.7
Debtor days	83.8	85.9	85.9	85.9
Creditor days	199.1	104.9	104.9	104.9
Asset Turnover	0.9	0.7	0.7	0.8
EBITDA conversion rate	76.8	28.1	56.7	75.7
Return Ratios (%)				
RoE	16.5	15.0	11.3	15.4
RoCE	16.2	10.9	9.5	12.7
RoIC	23.0	10.4	10.1	13.4
Valuation Ratios (x)				
P/E	53.2	47.1	57.0	36.8
EV / EBITDA	27.9	33.8	36.8	28.7
EV / Revenues	8.9	8.6	7.7	6.9
Market Cap / Revenues	8.5	7.8	7.0	6.3
Price to Book Value	8.0	7.0	6.4	5.7
Solvency Ratios				
Debt / Equity	0.5	0.9	0.8	0.7
Debt/EBITDA	1.5	3.7	4.1	3.2
Current Ratio	3.5	4.4	4.5	4.5

Source: Company, ICICI Direct Research

RATING RATIONALE

ICICI Direct endeavours to provide objective opinions and recommendations. ICICI Direct assigns ratings to its stocks according to their notional target price vs. current market price and then categorizes them as Buy, Hold, Reduce and Sell. The performance horizon is two years unless specified and the notional target price is defined as the analysts' valuation for a stock

Buy: >15%

Hold: -5% to 15%;

Reduce: -15% to -5%;

Sell: <-15%



Pankaj Pandey

Head – Research

pankaj.pandey@icicisecurities.com

ICICI Direct Research Desk,
ICICI Securities Limited,
1st Floor, Akruiti Trade Centre,
Road No 7, MIDC,
Andheri (East)
Mumbai – 400 093
research@icicidirect.com

ANALYST CERTIFICATION

I/We, Siddhant Khandekar, Inter CA, Utkarsh Jain, MBA, Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products.

ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager and Research Analyst. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number – INH000000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Retail Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Institutional Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or actual/ beneficial ownership of one percent or more or other material conflict of interest various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.